摘要
目的评价ERCCI和P53在Ⅱ期结肠癌中FOLFOX方案辅助化疗获益的预测作用。方法回顾性收集58例Ⅱ期结肠癌,均接受12疗程FOLFOX方案辅助化疗;利用免疫组化方法检测ERCC1和P53的表达水平,并评价它们的表达水平与无病生存期的关系。结果在58例患者中,ERCC1的表达率为62.1%,ERCC1阴性表达患者的中位DFS明显高于阳性表达者(6.2 vs 5.1年,P=0.02);而P53的表达率为48.3%,P53阴性与阳性表达患者的中位DFS差异无统计学意义(5.3 vs 5.6年,P=0.93)。结论在Ⅱ期结肠癌中,ERCC1表达可能预测FOLFOX6辅助化疗的获益减少。
Objective To evaluate the predictive role of ERCCI and P53 on benefit from FOLFOX adjuvant chemotherapy. Methods 58 stage Ⅱ colon cancer patients receiving FOLFOX adjuvant chemotherapy were included. Testing the expression level of ERCCI and P53 by immunohistochemistry method and assessing the association of expression level with disease-free survival（DFS）. Results Among 58 patients, the rate of ERCCI expression was 62.1%, and ERCCI-negative patients had significantly longer DFS than patients with ERCClexpression （6.2 vs 5.1 years, P=0.02）. However, the rate of P53 expression was 48.3%, the DFS between P53-negative and positive patients was not of statistically significant difference（5.3 vs 5.6 years, P=0.93）. Conclusion In patients with stage Ⅱ colon cancer, ERCCI expression may predict less benefit from FOLFOX adjuvant chemotherapy.
出处
《中国医药科学》
2014年第11期20-22,38,共4页
China Medicine And Pharmacy
基金
广东省中山市科技计划项目(20113A045)
